Advancing RNA

ARW ON RNA

Inside Alnylam's Playbook For High Volume siRNA Production

As one of the first companies to establish a chemoenzymatic ligation platform, Alnylam's Maines and Nechev are in the perfect position to espouse wisdom on the practical aspects and remaining challenges of implementing enzymatic ligation at a large scale. Here in this installment, Maines and Nechev outline what they’ve learned thus far about the science of enzymatic ligation, while also paying credence to the unknowns and existing barriers that, as a frontrunner, Alnylam will inevitably (but willingly) be tasked with facing in the future.

OUR EXPERT NETWORK

Dual Centrifugation And The Next Phase Of Lipid Nanoparticle Development
Dual centrifugation enables rapid, small-scale LNP screening with high encapsulation, reproducibility, and preserved RNA integrity — offering a flexible bridge between benchtop discovery and scalable manufacturing.
The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology
Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.
Proteomics Tools: A Resurrection
For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.
Engineering Translation: How tRNA Therapeutics Expand The RNA Toolkit
Engineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis.
Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage
Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.

WEBINARS

Optimizing Antibody Variant Capture: Strategies To Combat Aggregation, Impurities, And Low Yields

Imagine The Future: An Enhanced Oligonucleotide Synthesis Process

Your AKTA Oligosynt™ System : It's More Than A Machine

Take The Wheel And Drive Your Oligo Synthesis Where You Want

Five Practical Considerations To Move From Concept To Clinic

Hear From The Experts: LNPs Driving The Future Of Cell Therapy

Manufacturing Made More Robust And Customer-Centric

Robust And Cost-Effective mRNA Capping

MEET ARW

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.

Start the conversation by following me on LinkedIn!

RNA HOT TAKES

VIRTUAL EVENTS

More Virtual Events

NEWSLETTER ARCHIVE

More Newsletters